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ischemia–reperfusion injury via activating eNOS 
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Abstract 
Background: Diabetic patients are more sensitive to myocardial ischemic injury than non-diabetic patients. Silent 
information regulator 1 (SIRT1) is a nicotinamide adenine dinucleotide-dependent histone deacetylase making the 
heart more resistant to ischemic injury. As SIRT1 expression is considered to be reduced in diabetic heart, we therefore 
hypothesized that up-regulation of SIRT1 in the diabetic heart may overcome its increased susceptibility to ischemic 
injury.
Methods: Male Sprague–Dawley rats were fed with high-fat diet and injected with streptozotocin once to induce 
diabetes. Diabetic rats received injections of adenoviral vectors encoding SIRT1 (Ad-SIRT1) at five myocardial sites. 
Four days after adenoviral injection, the rats were subjected to myocardial ischemia and reperfusion (MI/R). Outcome 
measures included left ventricular function, infarct size, cellular death and oxidative stress.
Results: Delivery of Ad-SIRT1 into the hearts of diabetic rats markedly increased SIRT1 expression. Up-regulation of 
SIRT1 in diabetic hearts improved cardiac function and reduced infarct size to the extent as in non-diabetic animals 
following MI/R, which was associated with reduced serum creatine kinase-MB, lactate dehydrogenase activities and 
cardiomyocyte apoptosis. Moreover, Ad-SIRT1 reduced the increase in the superoxide generation and malonaldialde-
hyde content and simultaneously increased the antioxidant capability. Furthermore, Ad-SIRT1 increased eNOS phos-
phorylation and reduced eNOS acetylation in diabetic hearts. NOS inhibitor L-NAME inhibited SIRT1-enhanced eNOS 
phosphorylation, and blunted SIRT1-mediated anti-apoptotic and anti-oxidative effects and cardioprotection.
Conclusions: Overexpression of SIRT1 reduces diabetes-exacerbated MI/R injury and oxidative stress via activating 
eNOS in diabetic rats. The findings suggest SIRT1 may be a promising novel therapeutic target for diabetic cardiac 
complications.
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Background
Type 2 diabetes mellitus has reached epidemic propor-
tions in most developed and many developing nations [1]. 
Numerous clinical studies have shown that cardiovascu-
lar diseases are the leading cause of morbidity and mor-
tality among diabetic patients [2]. People with diabetes 
have two to five times higher risk of developing ischemic 
heart disease than nondiabetic population [3]. Diabetic 
patients are more susceptible to myocardial ischemic 
injury than non-diabetic patients, with worse clinical 
outcomes and greater mortality [4–6]. In recent years, 
the pursuit for novel rescue approaches that are effec-
tive in diabetic ischemic myocardium has significantly 
increased. In particular, identifying the molecular basis 
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linking diabetes with increased susceptibility to ischemic 
injury is not only scientifically important, but may reveal 
potential new therapeutic targets against ischemic heart 
diseases under diabetic condition.
Silent information regulator 1 (SIRT1) is a nicotina-
mide adenine dinucleotide (NAD+)-dependent histone 
deacetylase involved in the regulation of metabolism, 
cell survival, differentiation, and longevity [7, 8]. SIRT1 
exerts beneficial effects on glucose-lipid homeosta-
sis and insulin sensitivity in diabetes from both animal 
studies and clinical research [9, 10]. Importantly, endog-
enous SIRT1 is involved in cardioprotection [11]. SIRT1 
expression was decreased in ischemic/reperfused hearts 
compared with sham hearts. Overexpression of SIRT1 
reduced myocardial ischemia/reperfusion (MI/R) injury 
in the heart, while cardiac specific downregulation of 
SIRT1 promoted myocardial injury following MI/R [12]. 
Both gain- and loss-of-function experiments suggest that 
SIRT1 makes the heart more resistant to MI/R injury.
Recently, several studies have indicated that SIRT1 
expression was significantly reduced in diabetic heart 
[13, 14], we therefore hypothesized that up-regulation of 
cardiac SIRT1 in the diabetic condition may overcome 
the increased susceptibility of the diabetic heart to I/R 
injury. To test this hypothesis, we employed adenovi-
ral vectors to selectively up-regulate the expression of 
SIRT1 in high-fat diet-fed and streptozotocin-induced 
(HFD-STZ) type 2 diabetic heart, then investigate 
whether this intervention was sufficient to reduce MI/R 
injury in diabetic rats and further explore the underlying 
mechanisms.
Methods
Induction of type 2 diabetic model
All animal experiments were conducted in accordance 
with the National Institutes of Health Guidelines for 
the Care and Use of Laboratory Animals (NIH Publica-
tion No. 85–23, revised, 1996). All study protocols were 
approved by the Fourth Military Medical University 
Committee (Shaanxi, China). The high-fat diet-fed and 
streptozotocin-induced (HFD-STZ) type 2 diabetic rat 
model was developed as described in our previous stud-
ies [15, 16] by providing HFD (D12451, Research Diets, 
NJ, USA) containing 45 % fat (kcal %), 35 % carbohydrate, 
and 20  % protein for 4  weeks and then one-shot injec-
tion of STZ (40 mg/kg i.p.) (Sigma, St. Louis, MO, USA). 
HFD was continuously fed after STZ injection, and then 
hyperglycemic rats (fasting blood glucose ≥11.1 mmol/L, 
from at least three samplings) 1 week after STZ injection 
were considered to have developed type 2 diabetes and 
were studied. The mortality rate of rats after STZ admin-
istration was 11.1  % (8 of 72 total rats died). A normal 
non-diabetic control group was included and fed with a 
control diet (10  % fat, 20  % protein, and 70  % carbohy-
drates, D12450H, Research Diets).
Cardiac overexpression of SIRT1 by adenovirus infection 
in vivo
Replication-deficient recombinant adenoviral vec-
tors encoding SIRT1 were generated using the Ad-
Easy system. In brief, the cDNA for SIRT1 was cloned 
into pMD19-T simple vector and then transferred into 
pAdTrack-CMV, resulting in pAdTrack-SIRT1. The shut-
tle vectors were used to generate recombinant adenoviral 
vectors encoding SIRT1 (Ad-SIRT1). Adenoviral vectors 
encoding green fluorescent protein (Ad-GFP) were used 
as control. Adenoviruses were purified by centrifugation 
and the adenoviral titer was determined by plaque assays.
The adenoviral-mediated gene delivery was performed 
as previously described [17, 18]. The rats were anesthe-
tized with 3  % pentobarbital sodium (60  mg/kg), and 
the heart was exposed through a left thoracotomy at the 
fourth rib. Adenoviral vectors (3 × 1010 pfu per rat) were 
administered by direct injection into the left ventricu-
lar free wall with a 30-gauge needle. The rats received 
intramyocardial injections of adenovirus expressing 
SIRT1 or GFP at five sites separated by about 2–3  mm 
around the left anterior descending (LAD) coronary 
artery. Four days after gene transfer, fasting blood sam-
ples were collected to analyze blood glucose, serum TC 
(total cholesterol) and TG (triacylglycerol) levels before 
the rats were subjected to MI/R (Fig.  1). The levels of 
serum TC and TG were analyzed using an automatic bio-
chemical analyzer (Advia 2400, Siemens, Germany).
Myocardial ischemia–reperfusion model
On the fourth day after adenoviral injection, the rats were 
re-anesthetized by intraperitoneal (i.p.) administration 
of 3  % pentobarbital sodium. Myocardial ischemia was 
induced by re-opening the chest followed by a slipknot 
(6–0 silk suture) around the LAD coronary artery about 
2–3  mm near its origin. Regional myocardial ischemia 
was verified by the development of a pale color in the 
ischemic area and changes of electrocardiogram (ST-seg-
ment elevation). The slipknot was loosened after 30 min 
of ischemia, and the ischemic myocardium was reper-
fused for 3  h. In sham rats, the silk suture was passed 
underneath the LAD artery without ligation.
Age-matched normal and diabetic male rats were 
randomly assigned into five experimental groups: (1) 
NS—non-diabetic sham rats; (2) NIR—non-diabetic rats 
receiving Ad-GFP were subjected to I/R; (3) DS—diabetic 
sham rats; (4) DIR—diabetic rats receiving Ad-GFP were 
subjected to I/R; (5) Ad.SIRT1—diabetic rats receiving 
Ad-SIRT1 were subjected to I/R. There are eight animals 
in each group.
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Assessment of SIRT‑1 activity
SIRT-1 activity in myocardial tissue was measured by a 
fluorometric assay kit (Cyclex, Japan). The principle of 
the kit is to determinate protease activity after modulat-
ing the protein through SIRT-1-mediated deacetylation. 
The peptide is labeled with fluorophore and quencher. 
The activity of SIRT-1 is directly proportional to the 
amount of fluorescence emitted by proteolytic cleavage 
of deacetylated peptide. Data were expressed as percent-
age activity.
Cardiac functional assessment
Cardiac function was monitored continuously during the 
whole period of I/R. A microcatheter was inserted into 
the left ventricular cavity under anesthesia through the 
right common carotid artery to assess the left ventricu-
lar developed pressure (LVDP). Hemodynamic data were 
recorded on a polygraph (RM-6240C; Chengdu Instru-
ment Co,. LTD, China). The maximal rate of rise and 
decline of left ventricular pressure (±LV dP/dtmax) were 
derived by digital computer algorithms.
Quantification of myocardial infarct size
After 6  h of reperfusion, myocardial infarct size (INF) 
was assessed as described before [16, 19]. LAD coro-
nary artery was retied and 1.5  ml of 2  % Evans blue 
dye was perfused into the LV cavity to stain the non-
ischemic region (area not at risk). The heart was rap-
idly excised and frozen at −20  °C. The frozen heart 
was cut into 1–2  mm thick sections perpendicular to 
the long axis of the heart. Slices were stained with 1  % 
triphenyltetrazolium chloride (TTC) in phosphate buffer 
(pH 7.4) for 15  min at 37  °C. TTC-unstained pale area 
(infarct zone), TTC-stained red area (ischemic but viable 
myocardium) and Evans blue-unstained regions (area-at-
risk, AAR) were analyzed by using an image analysis sys-
tem (Image Pro Plus 6.0; Media Cybernetics). Myocardial 
infarct size was determinated as a percent of infarct zone 
(INF) over total AAR (INF/AAR × 100 %).
Determination of serum creatine kinase‑MB and lactate 
dehydrogenase
After the 3 h reperfusion period, blood samples were col-
lected from the carotid artery. Serum creatine kinase-MB 
(CK-MB) and lactate dehydrogenase (LDH) levels were 
determined with the use of commercial kits (Nanjing 
jiancheng Bioengineering, China). The activities of these 
two enzymes were expressed as U/L.
Quantification of cardiomyocyte apoptosis
Cardiomyocyte apoptosis in the area at risk (AAR) has 
a significant effect on myocardial survival and function. 
After 3 h of reperfusion, tissue samples from the area at 
risk (AAR) were analyzed. Cardiomyocyte apoptosis was 
detected by terminal deoxynucleotidyl nick-end labeling 
(TUNEL) and caspase-3 activity assay. TUNEL labe-
ling was performed as described in previous study [6, 
20] by using an in  situ cell death detection kit (Roche). 
In brief, the slides were incubated with TUNEL reaction 
mixture and then counterstained with the 4′,6-diamino-
2-phenylindole (DAPI) to detect the nuclei. The apopto-
sis index was calculated as a percentage of the number 
Fig. 1 Schematic representation of experimental protocol. Diagram illustrates the diabetic induction period, adenoviral injection time point, 
ischemia/reperfusion period, and data acquisition time points. STZ streptozotocin, TC total cholesterol, TG triacylglycerol, CK-MB creatine kinase–MB, 
LDH lactate dehydrogenase
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of TUNEL-positive apoptotic cells over the total number 
of nucleated cells (DAPI staining). Myocardial caspase-3 
activity was determined as described before [21] by using 
a caspase colorimetric assay kit (Chemicon, Temecula, 
CA, USA) according to manufacturer’s protocol.
Quantification of superoxide generation, 
malonaldialdehyde (MDA) and total superoxide dismutase 
(SOD)
Lucigenin-enhanced chemiluminescence was used to 
assess superoxide production in heart tissue as described 
previously [22]. The results were expressed as relative 
light units (RLU) per second per milligram tissue weight 
(RLU/mg/s). The level of MDA and the activities of total 
SOD in myocardial homogenates were determined spec-
trophotometrically as previously described [21, 23] with 
the use of commercial kits (Nanjing jiancheng Bioengi-
neering, China).
Myocardial eNOS activity
The AAR of rat hearts was homogenized in 0.9 % NaCl 
(1:10, wt/vol). The tissue homogenate was centrifuged 
at 12,000g for 10  min at 4  °C, and the supernatant was 
collected to determine myocardial eNOS activity using a 
spectrophotometrical assay kit (Nanjing Jiancheng Bio-
engineering) as previously reported [21, 24].
Western blotting
Frozen AAR samples were homogenized in lysis buffer 
and protein concentrations were determined by using a 
BCA protein assay. After separated by electrophoresis on 
sodium dodecyl sulfate polyacrylamide gel electrophore-
sis (SDS-PAGE), the proteins were transferred to nitro-
cellulose membranes. The membranes were blocked with 
5 % skim milk for 1 h at room temperature and then incu-
bated with the appropriate primary antibodies including 
anti-SIRT1, anti-eNOS phosphorylation (p-eNOS) at Ser 
1177, anti-eNOS, anti-gp91phox (Cell Signaling Technol-
ogy) and anti-GAPDH (Wuhan Boster Biological Tech-
nology Ltd.) overnight at 4 °C. After three washing with 
phosphate buffer solution with tween-20 (PBST), the 
membrances were incubated with corresponding horse-
radish peroxidase-conjugated second antibodies. After 
additional PBST washes, the blots were evaluated by 
using an enhanced chemiluminescent system.
Quantitative real‑time PCR
Total RNA was extracted with Trizol reagent (Invit-
rogen, Shanghai, China) and was subjected to reverse 
transcription using superscript® III first-strand systhe-
sis system (Invitrogen, Shanghai, China) following the 
manufacturer’s instruction. Real-time PCR was carried 
out using Power SYBR green PCR master mix (Bio-rad). 
The following primer sequences were used: SIRT1 for-
ward GCAGGTTGCAGGAATCCAAA, reverse GGCA 
AGATGCTGTTGCAAAG; GAPDH forward GACATG 
CCGCCTGGAGAAAC, reverse AGCCCAGGATGCCC 
TTTAGT. Data were normalized relative to those for 
GAPDH expression using the 2−ΔΔCt method.
eNOS acetylation expression
Acetylated eNOS antibody was not commercially avail-
able up to now. The expression of eNOS acetylation 
was determined by co-immunoprecipitation assay as 
described in our previous study [24]. eNOS (1:1000 
crosslinked to magnetic beads (Dynal, Invitrogen) for 
extraction) was immunoprecipitated from 40  μg of 
myocardial tissue lysate, and the primary antibody for 
acetyl-lysine (Cell signaling) was employed to detect 
the association of the acetyl-lysine with eNOS by using 
immunoblotting.
Antagonize NOS with N‑nitro‑l‑arginine methyl ester 
(L‑NAME)
After adenoviral injection, eight rats from the Ad.SIRT1 
group were given L-NAME in their drinking water 
(200  mg/l) for 4  days before being subjected to MI/R 
(Ad.SIRT1  +  L-NAME group). The average dosage 
of L-NAME was nearly 15  mg/kg per day. This dose 
of L-NAME was based on the early studies [25, 26] in 
which near-maximal inhibition of NOS in the body was 
achieved.
Statistical analysis
All values are presented as mean  ±  SEM. Differences 
among comparisons were evaluated with one-way 
ANOVA followed by Bonferroni corrected t test where 
appropriate. P-values less than 0.05 were taken as statis-
tically significant. Statistical tests were performed using 
GraphPad Prism software version 5.0 (GraphPad Soft-
ware, Inc., San Diego, CA, USA).
Results
Characterization of animals
As shown in Table  1, compared with the non-diabetic 
rats, diabetic animals manifested significantly increased 
blood glucose, serum TC and TG, and decreased body 
weight, indicating that type 2 diabetic model was created 
in this study. Delivery of Ad-GFP or Ad-SIRT1 into the 
diabetic rat hearts did not show any significant effect on 
these parameters.
SIRT1 expression and activity were decreased in diabetic 
hearts
mRNA and protein expression of myocardial SIRT1 were 
significantly reduced in diabetic rats compared to control 
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non-diabetic animals (DS vs. NS or DIR vs. NIR, P < 0.05 
or P  <  0.01, Fig.  2a, b). Myocardial SIRT1 expression 
was also decreased after MI/R in control and diabetic 
rats compared with sham animals respectively (P < 0.05 
or P  <  0.01). Moreover, myocardial SIRT-1 activity was 
decreased in diabetic MI/R rats (DIR) compared to non-
diabetic MI/R (NIR) animals. These results suggested 
that diabetes or I/R alone could reduce SIRT1 expression, 
and significant down-regulated SIRT1 expression was 
induced in diabetic I/R hearts.
Up‑regulation of SIRT1 improved cardiac function 
in diabetic MI/R animals
As shown in Fig. 2, there were no significant differences 
in LVDP and ±LV dP/dtmax between non-diabetic sham 
(NS) and DM sham (DS) rats during I/R period. How-
ever, after MI/R, diabetic rats (DIR) showed aggravated 
myocardial functional impairment compared with non-
diabetic animals (NIR) as evidenced by decreased LVDP 
and ±LV dP/dtmax in the course of I/R (n = 8, P < 0.05 
or P  <  0.01). Delivery of Ad-SIRT1 markedly increased 
SIRT1 expression and activity in diabetic MI/R hearts 
(Fig.  2a–c). Compared with Ad-GFP-treated diabetic 
MI/R rats (DIR), up-regulation of SIRT1 (Ad-SIRT1) 
significantly elicited a significant recovery in LVDP and 
±LV dP/dtmax in diabetic MI/R rats (n =  8, P < 0.05 or 
P < 0.01, Fig. 2c–e). No significant difference was found 
in the changes of heart rate (HR) among all the groups 
(data not shown). These results showed that up-regula-
tion of SIRT1 alleviated cardiac dysfunction in diabetic 
rats subjected to MI/R.
Up‑regulation of SIRT1 attenuated MI/R injury in diabetic 
rats
To determine whether up-regulation of SIRT1 might 
reduce myocardial injury, serum CK-MB and LDH levels 
and myocardial infarct size were measured. Compared 
with non-diabetic sham (NS) animals, there were obvious 
myocardial infarction and increased serum CK-MB and 
LDH levels in non-diabetic MI/R (NIR) rats, which indi-
cated injury on cell membrane of cardiomyocytes after 
I/R leading to the release of cell content. The effects of 
Ad.SIRT1 on non-diabetic MI/R injury were assessed in 
our preliminary study. It was found that overexpression 
of SIRT1 significantly reduced infarct size and serum 
Table 1 Characterization of animals
Values presented are mean ± SEM. n = 9
DM high-fat diet-fed streptozotocin (HFD-STZ) diabetic group, TC total 
cholesterol, TG triacylglycerol
* P < 0.05, ** P < 0.01 vs. Non-DM




4.9 ± 0.6 18.6 ± 2.6* 20.1 ± 2.9* 19.1 ± 3.1*
TC (mmol/L) 1.42 ± 0.13 4.74 ± 0.16** 4.89 ± 0.21** 4.71 ± 0.24**
TG (mmol/L) 0.59 ± 0.08 1.21 ± 0.09* 1.36 ± 0.10* 1.41 ± 0.11*
Body weight 
(g)
281 ± 19 230 ± 17* 224 ± 18* 221 ± 16*
Fig. 2 Up-regulation of SIRT1 improved cardiac function after MI/R in diabetic rats. a mRNA expression of SIRT1. b Protein expression of SIRT1. c 
SIRT1 activity. d LVDP, left ventricular developed pressure. e, f ±LV dP/dtmax, the instantaneous first derivation of left ventricle pressure. NS, non-
diabetic sham rats; NIR, non-diabetic I/R rats receiving Ad-GFP; DS diabetic sham rats; DIR diabetic I/R rats receiving Ad-GFP; Ad.SIRT1, diabetic I/R 
rats receiving Ad-SIRT1. Values are mean ± SEM. n = 8. *P < 0.05, **P < 0.01 vs. NS; #P < 0.05, ##P < 0.01 vs. NIR; τP < 0.05, ττP < 0.01 vs. DIR
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CK-MB levels in non-diabetic rats (infarct size: 22.8 ± 2.9 
vs. 35.2  ±  3.4 in NIR group, CK-MB: 1687  ±  154 vs. 
2438 ± 189 in NIR group, n = 8, P < 0.05 or P < 0.01). As 
shown in Fig. 3, larger infarct size and further increased 
serum CK-MB and LDH levels were observed in dia-
betic MI/R (DIR) rats (n =  8, P < 0.05), suggesting that 
diabetes aggravated MI/R injury. Up-regulation of SIRT1 
significantly reduced infarct size and serum CK-MB and 
LDH levels in diabetic rats (Infarct size: 37.7  ±  3.1 vs. 
51.3 ±  4.2 in DIR group, n =  8, P < 0.05) to the extent 
as in non-diabetic animals following MI/R (Infarct size: 
37.7 ± 3.1 vs. 35.2 ± 3.4 in NIR group, n = 8, P > 0.1).
Apoptosis is another major form of cell death after 
I/R, we then investigate whether up-regulation of SIRT1 
could decrease cardiomyocyte apoptosis induced by 
MI/R. Compared with non-diabetic sham (NS) ani-
mals, the percentage of TUNEL-positive cells (Apop-
totic index: 21.8 ±  2.4  % of NIR vs. 5.6 ±  1.1  % of NS, 
Fig. 4a, n = 8, P < 0.01) and myocardial caspase-3 activ-
ity were significantly increased in the non-diabetic I/R 
(NIR) group. Similarly, diabetic MI/R rats showed fur-
ther increased myocardial apoptotic index and caspase-3 
activity compared with NIR group. Up-regulation of 
SIRT1 significantly reduced myocardial apoptosis in dia-
betic rats to the extent as in non-diabetic animals follow-
ing MI/R (Apoptotic index: 27.4 ± 3.2 % of Ad.SIRT1 vs. 
40.8 ± 4.6 % of DIR, Fig. 4a, n = 8, P < 0.01). All these 
results proved that up-regulation of SIRT1 reduced 
myocardial susceptibility to I/R injury in diabetic rats, 
which contributed to the improvement of cardiac func-
tion after MI/R.
Up‑regulation of SIRT1 attenuated I/R induced oxidative 
stress in diabetic rats
Compared with non-diabetic MI/R (NIR) group, myocardial 
superoxide generation was significantly increased in diabetic 
MI/R (DIR) group (P  <  0.01), and up-regulation of SIRT1 
inhibited superoxide accumulation (Fig. 5a, n = 6, P < 0.01 
vs. DIR group). gp91phox is a major component of NADPH 
oxidase, which is the most important superoxide-producing 
enzyme. Up-regulation of SIRT1 markedly reduced gp91phox 
expression in diabetic MI/R rats (Fig. 5b, n = 4, P < 0.05 vs. 
DIR group). Moreover, the level of MDA was determined as 
a biomarker of oxidative stress. There was a marked increase 
in MDA production in diabetic MI/R (DIR) group in com-
parison with the non-diabetic MI/R (NIR) group, which was 
reduced by Ad-SIRT1 administration (Fig. 5c). In contrast, 
Ad-SIRT1 administration increased myocardial antioxidant 
enzyme SOD activity in diabetic MI/R rats (Fig. 5d). These 
results suggested that SIRT1 reduced I/R-stimulated oxida-
tive stress in diabetic rats.
Up‑regulation of SIRT1 protects the diabetic heart 
against I/R injury via the modulation of eNOS activity
It has been proven that activation of eNOS exerts benefi-
cial effects on I/R hearts [27, 28]. To further investigate 
Fig. 3 Up-regulation of SIRT1 reduced MI/R injury in diabetic rats. a Serum creatine kinase-MB (CK-MB) levels. b Serum lactate dehydrogenase 
(LDH) levels. c Representative photos of myocardial infarct size. d Myocardial infarct size expressed as a percent of infarct area (INF) over total area 
at risk (AAR). NS, non-diabetic sham rats; NIR, non-diabetic I/R rats receiving Ad-GFP; DS, diabetic sham rats; DIR, diabetic I/R rats receiving Ad-GFP; 
Ad.SIRT1, diabetic I/R rats receiving Ad-SIRT1. Values are mean ± SEM. n = 8. **P < 0.01 vs. NS; ##P < 0.01 vs. NIR; τP < 0.05 vs. DIR
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the mechanisms underlying the SIRT1-mediated car-
dioprotection, we therefore measured eNOS activity 
and phosphorylated eNOS at Serine 1177 (activation 
state) and acetylated eNOS (deactivation state) in the 
hearts. As shown in Fig. 6, there was no significant dif-
ference in eNOS expression among all the groups, while 
Fig. 4 Up-regulation of SIRT1 inhibited cardiomyocyte apoptosis in diabetic hearts subjected to I/R. a Top Representative photomicrographs of 
TUNEL-positive apoptotic cardiomyocytes in the area at risk following MI/R (original magnification ×400). Bottom Quantitative analysis of myocar-
dial apoptosis. b Myocardial caspase-3 activity. NS, non-diabetic sham rats; NIR, non-diabetic I/R rats receiving Ad-GFP; DS, diabetic sham rats; DIR, 
diabetic I/R rats receiving Ad-GFP; Ad.SIRT1, diabetic I/R rats receiving Ad-SIRT1. Values are mean ± SEM. n = 8. **P < 0.01 vs. NS; ##P < 0.01 vs. NIR; 
τP < 0.05, ττP < 0.01 vs. DIR
Fig. 5 Up-regulation of SIRT1 attenuated oxidative stress in diabetic MI/R rats. a Cardiac superoxide generation. b Top representative blot images. 
Bottom quantitative analysis of gp91phox expression. c MDA, malondialdehyde contents. d SOD superoxide dismutase activity. NS, non-diabetic 
sham rats; NIR, non-diabetic I/R rats receiving Ad-GFP; DS, diabetic sham rats; DIR, diabetic I/R rats receiving Ad-GFP; Ad.SIRT1, diabetic I/R rats 
receiving Ad-SIRT1. Values are mean ± SEM. n = 4–6. **P < 0.01 vs. NS; #P < 0.05, ##P < 0.01 vs. NIR; τP < 0.05, ττP < 0.01 vs. DIR
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eNOS activity was significantly decreased in diabetic 
heart (DS) compared with that in non-diabetic control 
(NS). Western blot analysis demonstrated decreased 
eNOS phosphorylation and increased eNOS acetylation 
in diabetic heart. Ad-SIRT1 administration significantly 
increased eNOS activity and eNOS phosphorylation, and 
attenuated eNOS acetylation in diabetic heart (n = 4–6, 
P  <  0.05 vs. DIR group). These results suggested that 
up-regulation of SIRT1 might increase eNOS activity by 
enhanced phosphorylation of eNOS and reduced acetyla-
tion of eNOS.
To further ascertain the degree of involvement of 
eNOS in the cardioprotective effects of Ad-SIRT1, 
NOS inhibitor L-NAME was administered after adeno-
viral injection. As shown in Fig.  7, co-treatment with 
L-NAME significantly blocked eNOS phosphorylation 
and reduced eNOS activity although did not change acet-
ylation of eNOS. Moreover, the cardioprotective effects 
of Ad-SIRT1, as previous evidence by decreased myo-
cardial infarct size and caspase-3 activity and superoxide 
generation in diabetic rats, were abolished by L-NAME 
(Fig. 7d–f). These results suggested that up-regulation of 
SIRT1 attenuates MI/R-induced myocardial injury possi-
bly via modulating eNOS activity.
Discussion
In this study, we have demonstrated that SIRT1 is a pow-
erful regulator in diabetic MI/R injury. This conclusion is 
based on several novel findings. First, we have provided 
evidences that SIRT1 expression was decreased in diabetic 
heart, and overexpression of SIRT1 alleviated MI/R injury 
and improved cardiac function in diabetic rats. Second, 
SIRT1-mediated cardioprotection involved inhibition of 
oxidative stress. Third, the mechanisms of the cardiopro-
tection were mediated by modulation of eNOS activity.
Overwhelming epidemiological and clinical data have 
demonstrated that the diabetic heart is more sensitive to 
I/R injury [6, 29, 30]. It has been demonstrated that dia-
betes mellitus can exacerbate MIR injury and blunt the 
protective effect of various therapeutic agents [31, 32]. 
Thus, novel strategies and targets are urgently needed to 
reduce myocardial susceptibility to I/R injury in diabetic 
Fig. 6 SIRT1 overexpression increased eNOS activity and eNOS phosphorylation, and attenuated eNOS acetylation in diabetic heart. a Top repre-
sentative blot images. Bottom quantitative analysis of eNOS expression; b eNOS activity. c, d Top representative blot images. Bottom quantitative 
analysis of phosphorylated eNOS (p-eNOS) and acetylated eNOS (Ac-eNOS). NS, non-diabetic sham rats; DS, diabetic sham rats; DIR, diabetic I/R 
receiving Ad-GFP rats; Ad.SIRT1, diabetic I/R receiving Ad-SIRT1 rats. Values are mean ± SEM. n = 4–6. *P < 0.05 vs. NS; #P < 0.05 vs. DS; τP < 0.05 vs. 
DIR
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state. To address this issue, high-fat diet-fed and strep-
tozotocin-induced (HFD-STZ) type 2 diabetic animal 
model was developed in the present study. HFD elicited 
insulin resistance and STZ administration reduced insu-
lin levels, such that the animals were unable to maintain 
normal glucose levels and develop hyperglycemia. This 
model has been demonstrated to be suitable for studying 
the pathophysiology of type 2 diabetes as well as for test-
ing agents for the treatment of type 2 diabetes in several 
studies [16, 33, 34]. Markedly increased blood glucose 
level was also found in our diabetic animals. After devel-
oping this type 2 diabetic animal model, we observed 
that the diabetic rats showed aggravated MI/R injury and 
more severe myocardial functional impairment com-
pared with non-diabetic animals, which was consistent 
with the previous study [31].
Diabetes mellitus disrupts the cardiac gene expres-
sion profile, which might be involved in the development 
of cardiac implications [35]. SIRT1 is proved to be an 
endogenous protective molecule against MI/R-induced 
injury [12]. Therefore, we focused on the alteration of 
SIRT1 expression in diabetic heart. Our study indicated 
that mRNA and protein expression of myocardial SIRT1 
were significantly decreased in HFD-STZ-induced type 
2 diabetic rats. Previous studies have demonstrated that 
SIRT1 expression was reduced in STZ-induced type 1 
diabetic animals [14, 36]. Based on these data, it’s specu-
lated that SIRT1 might be partly reduced by hyperglyce-
mia, which is a common characteristic between type 1 
and type 2 diabetes.
It has been reported that resveratrol has the ability 
to stimulate SIRT1 and protects against diabetic car-
diomyopathy in experimental animals [14, 36]. However, 
resveratrol is not a direct activator of SIRT1 [37]. Some 
studies showed that resveratrol exerted its cardioprotec-
tive effects through multiple mechanisms including acti-
vation of AMPK pathway and modulation of calcium 
handling proteins [38, 39]. Moreover, resveratrol was 
found to improve whole-body glucose metabolism and 
decrease blood glucose level in diabetic animals [14], 
which may account for the cardioprotective effects of res-
veratrol. Our study indicated that cardiac overexpression 
of SIRT1 by adenovirus infection did not have significant 
influence on blood glucose and serum TC and TG. Impor-
tantly, overexpression of myocardial SIRT1 alleviated car-
diac dysfunction and myocardial injury (as evidenced by 
increased ±LV dP/dtmax and decreased serum CK-MB/
LDH activities, myocardial infarction and cardiomyocyte 
apoptosis) in diabetic rats to the extent as in non-diabetic 
animals subjected to MI/R, suggesting that cardiac spe-
cific up-regulation of SIRT1 is sufficient to reduce myo-
cardial susceptibility to I/R injury in diabetic rats.
Fig. 7 NOS inhibitor L-NAME inhibited cardioprotective effects of Ad-SIRT1. a eNOS activity, b Top representative blot images. Bottom quantita-
tive analysis of phosphorylated eNOS (p-eNOS); c Top representative blot images. Bottom quantitative analysis of acetylated eNOS (Ac-eNOS); d 
Myocardial infarct size expressed as a percent of infarct area (INF) over total area at risk (AAR); e Myocardial caspase-3 activity; f Cardiac superoxide 
generation. DIR, diabetic I/R rats receiving Ad-GFP; Ad.SIRT1, diabetic I/R rats receiving Ad-SIRT1; Ad.SIRT1 + L-NAME, diabetic I/R rats receiving Ad-
SIRT1 and L-NAME. Values are mean ± SEM. n = 4–6. *P < 0.05, **P < 0.01 vs. DIR; #P < 0.05, ##P < 0.01 vs. Ad.SIRT1
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Myocardial oxidative stress contributes importantly 
to vulnerability of diabetic myocardium to I/R injury [6, 
40]. As expected, diabetes enhances oxidative stress and 
reduces antioxidant defenses in I/R hearts as evidenced 
by increased superoxide generation and reduced SOD 
activity. Overexpression of SIRT1 not only decreased the 
generation of superoxide content but also increased anti-
oxidant enzyme SOD activity in the diabetic I/R heart 
tissue. NADPH oxidase is an important source of super-
oxide anion production [41]. Ad-SIRT1 administration 
decreased myocardial gp91phox (a critical component of 
NADPH oxidase) expression in diabetic I/R rats. MDA 
content in tissue usually reflects the level of oxidative stress 
[42]. Ad-SIRT1 administration also reduced MDA for-
mation in diabetic I/R heart tissue. Previous studies have 
reported that SIRT1 increased the expression of MnSOD 
(mitochondria-specific isoform of SOD) and attenuated 
mitochondrial oxidative damage induced by myocardial 
ischemia reperfusion injury [12, 43]. These results sug-
gested that Ad-SIRT1 administration may attenuate both 
mitochondria and NADPH oxidase-derived Reactive oxy-
gen species (ROS) production in diabetic I/R hearts.
Activation of eNOS has been demonstrated to clearly 
reduce myocardial infarct size and improve cardiac func-
tion in a variety of I/R models [27, 28]. Normally, eNOS 
phosphorylation and subsequent NO production exert 
anti-apoptotic and anti-oxidative effects in I/R hearts [44, 
45]. Decreased myocardial eNOS–NO availability has 
been found in both patients and animals with diabetes, 
which contributes to the development of diabetic com-
plications [46, 47]. Consistent with previous studies, we 
found reduced eNOS activity in diabetic hearts., while 
the expression of eNOS was not altered. These results 
suggest that posttranslational modifications of eNOS 
may account for the decreased eNOS activity in the set-
ting of diabetes.
SIRT1 is a histone deacetylase that plays an impor-
tant role in modulating eNOS activity. SIRT1 colocal-
izes with eNOS, and deacetylation by SIRT1 enhances 
eNOS activity. Inhibition of SIRT-1 activity can acety-
late eNOS and inhibit eNOS activity [48, 49]. In the pre-
sent study, reduced SIRT1 expression is associated with 
increased eNOS acetylation (deactivation state) and 
decreased eNOS phosphorylation (activation state) in 
diabetic hearts when compared with non-diabetic con-
trols. Moreover, up-regulation of SIRT1 reduced eNOS 
acetylation and enhanced the phosphorylation of eNOS 
and the activity of eNOS. These novel findings indicate 
that SIRT1 is a powerful regulator for maintaining nor-
mal eNOS function and active form in diabetic hearts.
To further clarify the role of eNOS in SIRT1-induced 
cardioprotective effects, NOS inhibitor L-NAME was 
applied. Co-treatment with L-NAME not only blocked 
SIRT1-induced eNOS activation, but also attenuated 
SIRT1-mediated anti-apoptotic and anti-oxidative effects 
in diabetic MI/R rats, as evidenced by increased myocar-
dial caspase-3 activity and superoxide generation. More-
over, inhibition of eNOS activity blunted the beneficial 
effects of SIRT1 on myocardial infarct size. These data 
indicate that SIRT1 may protect the diabetic rat heart 
against I/R injury via an eNOS-dependent mechanism. 
It should be noted that SIRT1 participates in cardiopro-
tection via a complex signaling network, including the 
PGC-1α, AMPK, eNOS and so on [11], and that activa-
tion of eNOS observed in our present study may be a 
dependent pathway by which SIRT1 exerts its cardiopro-
tective effects. Moreover, further studies are required to 
explore SIRT1 and eNOS effective strength in vitro.
Conclusions
The current study demonstrated that SIRT1 is a critical 
regulator in myocardial susceptibility to I/R injury under 
diabetic condition. Overexpression of SIRT1 reduces 
diabetes-exacerbated MI/R injury and oxidative stress via 
modulating eNOS acitivity in diabetic rats. The findings 
suggest SIRT1 may be a promising novel therapeutic tar-
get for diabetic cardiac complications.
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